Welcome to our dedicated page for Cabaletta Bio news (Ticker: CABA), a resource for investors and traders seeking the latest updates and insights on Cabaletta Bio stock.
Cabaletta Bio, Inc. (symbol: CABA) is a clinical-stage biotechnology company dedicated to the discovery and development of engineered T cell therapies for patients suffering from B cell-mediated autoimmune diseases. Utilizing its proprietary Chimeric AutoAntibody Receptor (CAAR) and Chimeric Antigen Receptor T cells for autoimmunity (CARTA) technologies, Cabaletta aims to provide targeted, effective, and potentially curative treatments.
The company's flagship product candidate, DSG3-CAART, is in Phase I clinical trials for treating mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Other promising candidates include MuSK-CAART for myasthenia gravis and FVIII-CAART for a subset of patients with hemophilia A. Cabaletta is also actively developing DSG3/1-CAART for mucocutaneous pemphigus vulgaris, with several products in various stages of preclinical and discovery phases.
In recent developments, Cabaletta Bio received approval from the U.S. FDA for its Investigational New Drug (IND) application for CABA-201, a fully human CD19-CAR T cell investigational therapy for generalized myasthenia gravis (gMG). This expands their portfolio into neurology, complementing prior clearances for lupus, myositis, and systemic sclerosis. The upcoming Phase 1/2 clinical trial for CABA-201 aims to test its efficacy in treating gMG patients, potentially offering a groundbreaking one-time dose treatment.
Furthermore, Cabaletta has secured multiple Fast Track Designations from the FDA for CABA-201 in conditions like dermatomyositis and systemic sclerosis, facilitating expedited development and review. These designations highlight the critical unmet needs in these patient populations and amplify Cabaletta’s commitment to pioneering advanced therapies.
Based in Philadelphia, PA, Cabaletta Bio continues to advance its innovative pipeline, guided by robust scientific research and strategic collaborations. The company is well-positioned financially, with adequate resources to fund its operations into the first half of 2026. Cabaletta's mission is to harness the power of engineered T cells to unlock transformative therapies, offering patients durable, drug-free remissions and improved quality of life.
Cabaletta Bio, Inc. (Nasdaq: CABA) presented new clinical data from its DesCAARTes™ trial at the EADV Congress, highlighting safety and persistence of DSG3-CAART therapy. The trial showed no dose-limiting toxicities, with one instance of grade 1 cytokine release syndrome. Importantly, while no consistent trends in antibody or disease activity reductions were noted, one patient showed significant improvement, including decreased steroid use. The company aims to prioritize a combination study using cyclophosphamide and intravenous immunoglobulin to enhance treatment efficacy.
Cabaletta Bio, a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced its participation in two investor conferences in September 2022. CEO Steven Nichtberger will engage in fireside chats at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12 and the H.C. Wainwright 24th Annual Global Investment Conference on September 14, both in New York. Live webcasts will be available on the company's website, with replays accessible for 30 days.
Cabaletta Bio, Inc. (Nasdaq: CABA) announced a late-breaking presentation at the 31st EADV Congress, scheduled from September 7-10, 2022, in Milan, Italy. The presentation will focus on new clinical data from cohorts A4 and A5 of the DesCAARTes™ trial, which investigates DSG3-CAART therapy for mucosal-dominant pemphigus vulgaris. Dr. David J. Chang will present preliminary findings on September 10, 2022. Additionally, Dr. Aimee Payne will discuss CAAR T cell advancements on September 9, 2022. The trial aims to determine the maximum tolerated dose and evaluate safety and efficacy of DSG3-CAART.
Cabaletta Bio (CABA) reported its financial results for Q2 2022, revealing R&D expenses of $9.5 million, up from $7.9 million in Q2 2021. General and administrative expenses increased slightly to $3.5 million from $3.3 million. As of June 30, 2022, the company held $96.8 million in cash, down from $122.2 million at year-end 2021, but still sufficient to support operations through Q1 2024. The company is advancing its DesCAARTes™ trial and expects to present significant clinical data at the upcoming EADV Congress in September 2022.
Cabaletta Bio, Inc. (Nasdaq: CABA) presented updated clinical data from its DesCAARTes™ trial at the ASGCT Annual Meeting. The interim data, involving 12 treated subjects across four cohorts, demonstrated a favorable safety profile for DSG3-CAART with no dose-limiting toxicities. Notably, a dose-dependent increase in persistence of DSG3-CAART cells was observed. The trial aims to escalate dosages while assessing the relationship between cell persistence and clinical response in patients with mucosal-dominant pemphigus vulgaris (mPV). The company is planning additional cohorts to augment its research.
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotech company, will have CEO Steven Nichtberger participate in a fireside chat at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 11:00 a.m. ET in Miami, FL. This event will highlight the company's focus on developing targeted cell therapies for autoimmune diseases. Interested individuals can access a live webcast on the company's website, with replays available for 30 days after the event.
Cabaletta Bio (CABA) reported Q1 2022 financial results, revealing a net loss of $12.9 million, or $0.45 per share. Research and development expenses surged to $9.2 million, driven by ongoing clinical trials. The cash balance fell to $109.2 million from $122.2 million, expected to support operations until Q3 2023. Key advancements include progress in the DesCAARTes™ trial for mucosal pemphigus vulgaris and plans to initiate a first-in-human trial for MuSK-CAART in myasthenia gravis, following FDA Fast Track Designation.
Cabaletta Bio (Nasdaq: CABA) announced the presentation of data from its lead programs, DSG3-CAART and MuSK-CAART, at various scientific meetings in May 2022. The DSG3-CAART trial is currently in Phase 1, targeting mucosal pemphigus vulgaris. Presentations will showcase early cohort data and further characterization of DSG3-CAART cells. The MuSK-CAART program will include preclinical studies on myasthenia gravis. Key events are at the American Society of Gene & Cell Therapy and Society for Investigative Dermatology meetings.
Cabaletta Bio, a clinical-stage biotechnology company (Nasdaq: CABA), announced that Gwendolyn Binder, Ph.D., will present a pre-recorded session at the 21st Annual Needham Virtual Healthcare Conference.
This presentation will be available on-demand starting April 12, 2022, at 3:45 p.m. ET, and can be accessed via the company’s website, with replays available for 30 days. Cabaletta Bio focuses on developing targeted T cell therapies for autoimmune diseases, with a growing pipeline that includes treatments for conditions like pemphigus vulgaris and myasthenia gravis.
Cabaletta Bio, Inc. (CABA) reported its fourth quarter and full year 2021 financial results and provided a business update. The company ended 2021 with $122.2 million in cash, funding operations through Q3 2023. Significant advancements include the DesCAARTes™ trial, showing positive early results in cohorts, and the MuSK-CAART IND application cleared by the FDA with Fast Track Designation granted. Upcoming data presentations are scheduled for mid-2022, which are anticipated to provide insights into ongoing trials.
FAQ
What is the current stock price of Cabaletta Bio (CABA)?
What is the market cap of Cabaletta Bio (CABA)?
What is Cabaletta Bio's primary focus?
What are some of Cabaletta Bio's key product candidates?
What is CABA-201 and why is it significant?
Has Cabaletta Bio received any regulatory designations?
Where is Cabaletta Bio headquartered?
What is the current financial condition of Cabaletta Bio?
What stages are Cabaletta Bio's clinical trials in?
What makes Cabaletta Bio's technology proprietary?
What recent achievements has Cabaletta Bio made?
How does Cabaletta Bio aim to impact patient care?
